Home/Pipeline/DCVax®-Prostate

DCVax®-Prostate

Prostate Cancer

Pre-clinicalActive

Key Facts

Indication

Prostate Cancer

Phase

Pre-clinical

Status

Active

Company

Northwest Biotherapeutics

About Northwest Biotherapeutics

Northwest Biotherapeutics is a pioneering developer of personalized cancer vaccines utilizing its DCVax® dendritic cell platform. The company's most advanced candidate, DCVax®-L, has completed a Phase III trial for glioblastoma (GBM) and represents a significant potential advancement in a difficult-to-treat cancer. While navigating a challenging financial and regulatory path, the company is expanding its manufacturing capabilities in the UK and advancing earlier-stage programs for other solid tumors. Its long-term success hinges on securing regulatory approvals, establishing commercial manufacturing, and demonstrating its platform's efficacy beyond GBM.

View full company profile

Therapeutic Areas

Oncology Glioblastoma Solid Tumors

Other Prostate Cancer Drugs

Drug	Company	Phase	Status
APVO442	Aptevo Therapeutics	Preclinical	Active
APVO452	Aptevo Therapeutics	Discovery	Active
BIO 300	Humanetics Corp.	Not Specified	Active
Opaganib	RedHill Biopharma	Phase 2	Active
Small-Molecule Therapeutic	AIkido Labs	Pre-clinical	Active
Leronlimab	CytoDyn	Preclinical	Phase in progress
CROES Registry	AngioDynamics	Post-Market Registry	Active
Cannabics® PRST-33	CNBX Pharmaceuticals	Discovery	In vitro POC
HDP-103	Heidelberg Pharma	Preclinical	Active
ENV105	Kairos Pharma	Phase 2	Active
AI for Prostate Cancer	Invenio Imaging	Research	Active
Mitomic™ Test for Prostate Cancer	MDNA Life Sciences	Development/Validation	Active